The Tobacco Bill in Kenya has sparked debate, with critics arguing that it fails to distinguish between various nicotine products. The bill refers to all nicotine products as "tobacco products," despite some containing no tobacco. Scientifically, this approach is problematic as it overlooks the varying levels of health risks associated with different products. Cigarettes, vapes, and oral nicotine pouches all contain nicotine but expose users to different toxicants.
The health risks associated with nicotine products are largely linked to the combustion process involved in smoking. Burning tobacco generates thousands of chemicals, including toxic and carcinogenic substances. In contrast, smoke-free nicotine products avoid this combustion process, reducing the risk of smoking-related diseases. However, this does not mean that vapes or nicotine pouches are harmless. The UK government's evidence review found that vaping represents only a small fraction of the risks of smoking in the short and medium term.
There is robust evidence supporting the use of alternative nicotine products as tools to quit smoking. A Cochrane living systematic review updated in August found high-certainty evidence that nicotine vapes increase quit rates compared with conventional nicotine replacement therapy. Nicotine pouches are a newer category, and while the evidence base is less mature, the US Food and Drug Administration authorised 20 nicotine pouch products to carry a modified-risk claim in June.
The issue of flavours in nicotine products also requires a nuanced approach. Non-tobacco flavours are commonly used by adults who vape, and research has found that adults using flavoured products are twice as likely to quit cigarettes than those using tobacco flavours. Flavours can help smokers quit by making alternative products distinct from cigarettes. However, regulation and enforcement should address youth access, advertising, packaging, and product quality without depriving adults of potentially effective quit aids.
The Harm Reduction Society of Kenya advocates for a science-based approach to regulating nicotine products. The organisation's tobacco programme is based on the principle that adults who continue to smoke should move to alternatives that expose them to fewer toxicants. The current hearings on the Tobacco Control (Amendment) Bill raise important scientific issues for Kenya, including the need to acknowledge that cigarettes, vapes, and nicotine pouches are not equally harmful.
Public health is best served when the distinctions between nicotine products are accurately communicated, and policy debates reflect the strength, limitations, and direction of the evidence. The science on nicotine products is continuing to develop, but it is already clear that combustion, relative risk, and the difference between smoking and smoke-free nicotine use matter. Effective regulation can help reduce smoking-related diseases while acknowledging that nicotine products are not risk-free.
The Harm Reduction Society of Kenya's secretary-general emphasised the importance of a science-based approach to regulating nicotine products. The organisation hopes that Kenya will get a Tobacco Bill that reflects the scientific evidence and acknowledges the differences between various nicotine products. This approach will help ensure that public health policy is guided by the best available evidence, ultimately reducing the burden of smoking-related diseases in Kenya.
Key points
- The Tobacco Bill in Kenya has sparked debate over its approach to regulating nicotine products as a single category, ignoring scientific differences between cigarettes, vapes, and nicotine pouches.
- Smoke-free nicotine products, such as vapes and nicotine pouches, pose lower health risks compared to cigarettes due to the absence of combustion.
- Effective regulation of nicotine products should acknowledge the differences in health risks and be guided by scientific evidence to reduce smoking-related diseases.
